You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cardiovascular conditions
  5. Embolism and thrombosis

Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism

  • Technology appraisal guidance
  • Reference number: TA287
  • Published:  26 June 2013
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 The technology
  • 3 The manufacturer's submission
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Recommendations for further research
  • 7 Appraisal Committee members and NICE project team
  • 8 Sources of evidence considered by the Committee

6 Recommendations for further research

6.1

There have been no head-to-head trials of rivaroxaban compared with a low molecular weight heparin for people who have cancer and experience an acute pulmonary embolism or deep vein thrombosis. As in NICE's technology appraisal guidance on rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism it is recommended that further research should be carried out.

6.2

Research into the long-term treatment effects of rivaroxaban is needed.


Next page 7 Appraisal Committee members and NICE project team Previous page 5 Implementation
Back to top